Andrew J. Oakley - Vice President, Chief Financial Officer, Member of the Actelion Executive Committee

Andrew J. Oakley, a citizen of both Australia and the United Kingdom, holds an MBA from London Business School. He has been a member of the Australian Institute of Chartered Accountants since 1987. In his last position before joining Actelion, Mr. Oakley served in a senior finance capacity for the global holding companies of Accenture. In his career, he has also held executive positions in the finance departments of two major multinational building material companies. In addition, he also spent several years as an equity analyst with banks in Australia, the United Kingdom and the United States.

Simon Buckingham - President Corporate and Business Development, Member of the Actelion Excecutive Committee

Simon Buckingham is responsible for managing the future strategic direction of the company, reporting to the CEO. This role specifically involves leading and integrating the functions of Strategic Planning, Business Development and Portfolio Management. Before taking up this role at Actelion, he was President of North America and Asia Pacific. He was responsible for Actelion's sales, marketing, medical and regulatory activities in the US from the subsidiary‘s inception in South San Francisco in 2000. He has presided over the successful launch of Tracleer® in the US, Canada and Australia, as well as Zavesca® in the US.His experience in pharmaceutical sales, marketing and development spans over 15 years. He joined Actelion early in 2000 and, prior to that, held positions in sales, marketing and development at Parke-Davis US, the pharmaceutical division of Warner Lambert, and at Roche. He is a veterinarian by training, has a PhD and a Graduate Management Qualification.

Otto Schwarz - President Business Operations, Member of the Actelion Excecutive Committee

Otto joined Actelion as Head of Business Operations and Executive Committee Member in 2008. Prior to joining Actelion, he was Executive Vice-President Commercial Operations at Nycomed (former Altana Pharma AG) where he oversaw commercial operations in more than 40 countries. Previously, Otto served almost twenty years at Eli Lilly and Schering-Plough providing him with the opportunity to either lead or participate in major drug launches and major strategic alliances with third parties. Otto is an Austrian National with a PhD in pharmaceutical chemistry from Vienna University.

Isaac Kobrin - Senior Vice President, Head of Clinical Development, Member of the Actelion Executive Committee

Isaac Kobrin is an internist educated in Israel with further training (Fullbright Fellowship) at the Ochsner Medical Foundation in New Orleans, LA, mainly in the cardiovascular and nephrology fields. He joined the clinical cardiovascular development department at F. Hoffmann-La Roche in 1989. During his 10 years at F. Hoffmann-La Roche, he was responsible for the worldwide clinical development of key compounds within the company's cardiovascular portfolio (Phase I to NDA). In 1997 he became Group Leader of the cardiovascular development group. He is the author of more than 80 manuscripts and received the 1997 Hoffman-La Roche Research Prize. Isaac joined Actelion in September 1999 as Head of Clinical Development.

Louis de Lassence - Vice President, Head of Corporate Services, Member of the Actelion Executive Committee

After graduating from a business school in Paris in 1976, Louis de Lassence started as an external auditor and obtained degrees in Accounting. From 1982 onwards, he spent 18 years with Roche where he gained broad experience in Finance and Administration. His last positions there were finance manager of Roche in Brussels, assistant of the vice-chairman of the group and finance manager of Pharma International, the department in charge of Pharma sales in Central and Eastern Europe, Africa, Middle-East and Central and Near Asia.

Roland Haefeli - Vice President, Head of Investor Relations and Public Affairs, Member of the Actelion Executive Committee
Roland Haefeli joined Actelion as its Head of Investor Relations & Public Affairs in 2001. A historian and political economist with advanced degrees from the University of Bern (Switzerland) and UNC – Chapel Hill (USA), he started his career in the pharmaceutical industry as a corporate spokesperson for Roche. He also worked as head of media relations for other companies, including Serono. In his early career, a stock market training program in a Swiss Private Bank was followed by several years as a news writer, presenter and editor for several print and electronic media operations. He also served two years as a Delegate for the International Committee of the Red Cross (ICRC) in Bosnia and Rwanda.

Walter Fischli - Senior Vice President, Head of Drug Discovery Molecular Biology & Biochemistry, Founder
Walter Fischli is a biochemist educated at the Swiss Institute of Technology (ETH) Zurich, with further training in molecular biology and organic chemistry. During a research fellowship at the Addiction Research Foundation, Stanford University, he worked in the endorphin field and co-discovered and characterized the family of dynorphins. During his 15 years at F. Hoffmann-La Roche, he led drug discovery projects such as the renin inhibitor program and the atrial natriuretic factor program. He also brought two renin inhibitors to clinical trials. Walter Fischli developed novel screening technologies and discovered several novel classes of chemical lead compounds, both of which allowed the development of the first orally active endothelin antagonists and non-peptide renin inhibitors. In 1993, he received the Hoffmann-La Roche Research Prize.

Martine Clozel - Senior Vice President, Head of Drug Discovery Pharmacology & Pre- clinical Development
Martine Clozel is a pediatrician specialized in neonatal intensive care, who was educated at the University of Nancy, France. She received further training in physiology and pharmacology at McGill University, Montreal, and at the University of California, San Francisco. During her 11 years at F. Hoffmann-La Roche, she initiated and led the project on endothelin and endothelin receptor antagonists, leading to the clinical development of Tracleer™(bosentan) (the first of its class) and three other development candidates including Veletri™(tezosentan).

Thomas Weller - Vice President, Head of Drug Discovery, Chemistry
Thomas Weller studied chemistry at the ETH Zurich and completed his PhD thesis under Professor D. Seebach with further training at Columbia University New York under Professor G. Stork. He spent 16 years in the drug discovery unit at F. Hoffmann-La Roche as group leader and later on as area head of chemistry in thrombosis and arteriosclerosis. His projects included the isolation of active principles from fermentation broths, medicinal chemistry on PAF antagonists, thrombin inhibitors, vitronectin receptor antagonists and oxidosqualene cyclase inhibitors. In the field of fibrinogen receptor antagonists two of his molecules, lamifiban and sibrafiban, were among the most advanced of their class and progressed through clinical development up to phase III trials.

Marian Borovsky - Vice President, General Counsel & Corporate Secretary
Marian Borovsky joined Actelion as its General Counsel in 2000, taking on responsibility for all legal, intellectual property and insurance issues of the Actelion group. In addition to his position as General Counsel, he was nominated Corporate Secretary to the Board of Directors of Actelion Ltd in 2003. Marian earned his JD from the University of Basel and is admitted to the Bar. He started his professional career as an attorney at law with an insurance company and subsequently worked as a legal and tax adviser for an international audit and consulting firm. During this time, he also acted as a lecturer for commercial law for prospective auditors and accountants. In addition, he completed a secondment to an international business law firm in London and is a qualified business mediator.